ArticleFrontiers in oncology2026
NSUN3 promotes oral squamous cell carcinoma progression through autophagy activation and FOXO pathway modulation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma (OSCC) is a prevalent malignancy with high rates of lymph node metastasis and recurrence, contributing to persistently poor clinical outcomes. RNA 5-methylcytosine (m Methods: NSUN3 expression profiles were characterized in OSCC tissues and cell lines using immunohistochemistry, qRT-PCR, and Western blot. Clinicopathological correlations and survival analyses were performed on a cohort of 60 OSCC patients. NSUN3 was knocked down in SCC15 and SCC25 cells using lentiviral shRNA. Cell proliferation, migration, and invasion were assessed by CCK-8, wound-healing, and Transwell assays. Autophagy activity was evaluated by immunofluorescence (LC3 puncta formation), electron microscopy (autophagosome quantification), and Western blot (LC3-II/I ratio, Beclin1, P62/SQSTM1). The autophagy agonist rapamycin was used to rescue phenotypic changes. The activity of the FOXO pathway was assessed by detecting phospho-FOXO1/FOXO3. Results: NSUN3 was significantly upregulated in OSCC tissues and cells. Elevated NSUN3 expression, along with advanced pTNM stage and lymph node metastasis, constituted independent risk factors for poor overall survival. NSUN3 knockdown suppressed OSCC cell proliferation, migration, and invasion. Mechanistically, NSUN3 depletion inhibited autophagy, as evidenced by reduced LC3 puncta, decreased autophagosome number, lower Beclin1 expression, a reduced LC3-II/I ratio, and increased P62/SQSTM1 levels. Rapamycin treatment reversed these effects and partially restored malignant phenotypes. Furthermore, NSUN3 knockdown increased the phosphorylation (inactivation) of FOXO1 and FOXO3, thereby suppressing the FOXO signaling pathway. Conclusion: NSUN3 is overexpressed in OSCC and is an independent prognostic factor. It promotes OSCC progression by enhancing autophagy, potentially through modulating the FOXO pathway. Targeting NSUN3 may represent a novel therapeutic strategy for OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.